{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T09:02:41Z","timestamp":1789635761950,"version":"4.0.0"},"reference-count":45,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T00:00:00Z","timestamp":1789516800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Background: Concurrent chemoradiotherapy (cCRT) followed by 1 year of consolidation durvalumab remains the standard of care for unresectable stage III non-small cell lung cancer (NSCLC), yet long-term survival is still limited and around 20% of patients present locoregional relapse. Hypofractionation may improve the therapeutic ratio by increasing the biologically effective dose (BED), shortening overall treatment time (OTT) and potentially mitigating radiation-induced lymphopenia. Objective: To identify which patients with unresectable stage II\u2013III NSCLC may benefit most from radical-intent hypofractionated radiotherapy (HypoRT), with or without systemic therapy, and to define the technical aspects, contouring margins, and dosimetric requirements necessary for the safe use of hypofractionated schedule. Methods: A systematic search of PubMed, EMBASE, CENTRAL and Web of Science (January 2010\u2013January 2024, English language) was performed following PRISMA principles. Eligible studies included unresectable NSCLC treated with a BED10 &gt; 40 Gy, allowing induction systemic or targeted therapy; reviews were included for context. Records were screened by six independent reviewers. Studies were classified as non-photon vs. photon, and photon studies were further divided into non-concurrent and concurrent strategies. Clinical outcomes (dose, fractionation, biologically effective Dose for alpha\/beta:10 (BED10), equivalent dose of 2 Gy\/fraction (EQD2), overall treatment time (OTT), follow-up (FU), median progression-free survival (mPFS), median Overall Survival (mOS), local control (LC), grade \u2265 3 toxicity (G3) and technical variables (immobilization, simulation, GTV imaging, CTV\/PTV margins, delivery, image-guided radiotherapy (IGRT), organ at risk (OAR) constraints) were extracted. Results: Of 340 records (170 duplicates), 26 studies including stage II\u2013III disease were analyzed (1155 patients): 1 prospective cohort, 5 phase I, 12 phase II, 1 phase III and 2 phase I\/II dose-escalation trials, 2 carbon-ion and 3 proton series. Of these, 13 were photon-based studies with contemporary simulation techniques. Two clinically distinct scenarios emerged. Group A (non-concurrent platinum-based strategies; 166 patients with modern 4DCT simulation) showed wide variability, ranging from a simultaneous-integrated-boost regimen to 75 Gy with 0% grade \u2265 3 toxicity and mPFS 40 months to a chemotherapy-driven schedule with 70% grade 4 chemo-related toxicity. Only one phase III trial was identified, reporting a 2-year local control of 85.8%. Group B (concurrent strategies; nine of the 14 platinum-based studies retrieved, namely those using modern simulation techniques) achieved a median BED of 89.7 Gy to the highest dose-volume, median of OS 20 months and toxicity GIII \u2265 ranging 10\u201320%, with a median study-level grade 5 toxicity of 5.5% (range 0\u201317.8%; 34 fatal events among 431 evaluable patients, 7.9%), rising to 20.8% (11\/53) in the most escalated randomized arm and 22.2% (2\/9) in the highest dose-escalation cohort; adaptive SABR boost to 70 Gy\/15 fr delivered high local control but clinically meaningful fatal toxicity. Fatal toxicity was confined to schedules exceeding BED10 100 Gy delivered to the whole tumor volume with concurrent platinum, whereas an equivalent BED restricted to a metabolically defined subvolume without concurrent chemotherapy produced no grade \u22653 events. Conclusions: Radical-intent hypofractionation is feasible across both unfit and fit unresectable stage II\u2013III NSCLC populations, but the randomized evidence remains scarce and heterogeneous. Benefit appears most consistent when high BED is delivered with strict normal-tissue sparing in carefully selected patients using modern 4DCT-based simulation, IGRT and intensity-modulated delivery. The pattern of fatal toxicity with aggressive concurrent systemic treatments and dose escalation schedules argues for caution and for prospective trials with harmonized minimum technical standards.<\/jats:p>","DOI":"10.3390\/cancers18182997","type":"journal-article","created":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T10:09:17Z","timestamp":1789553357000},"page":"2997","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Hypofractionation in Unresectable Stage II\u2013III NSCLC: A Systematic Technical Review and Practical Recommendations"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6394-7750","authenticated-orcid":false,"given":"Gabriela","family":"Antelo","sequence":"first","affiliation":[{"name":"Radiation Oncology Department, Hospital Clinic of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4637-3473","authenticated-orcid":false,"given":"Miriam","family":"N\u00fa\u00f1ez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Institut Catal\u00e0 d\u2019Oncologia, 08908 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0751-679X","authenticated-orcid":false,"given":"Josep","family":"Carreras","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Hospital Clinic of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3604-3956","authenticated-orcid":false,"given":"Nuria","family":"Farre-Bernardo","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Hospital Sant Pau, 08041 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0130-321X","authenticated-orcid":false,"given":"Paloma Sosa","family":"Fajardo","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Hospital Virgen del Roc\u00edo, 41013 Sevilla, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inmaculada","family":"Romero-Palomar","sequence":"additional","affiliation":[{"name":"Gregorio Mara\u00f1\u00f3n General University Hospital Library, 28007 Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2766-5972","authenticated-orcid":false,"given":"Nuria Rodr\u00edguez de","family":"Dios","sequence":"additional","affiliation":[{"name":"Hospital Clinico Universitario de Santiago de Compostela, 15706 Santiago de Compostela, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1327-5367","authenticated-orcid":false,"given":"Arturo","family":"Navarro-Martin","sequence":"additional","affiliation":[{"name":"Radiation Oncology Department, Hospital Clinic of Barcelona, 08036 Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,9,16]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1200\/JCO.21.01308","article-title":"Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non\u2013Small-Cell Lung Cancer","volume":"40","author":"Spigel","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/j.jtho.2024.09.1437","article-title":"Accelerated hypofractionated radiotherapy for locally-advanced non-small cell lung cancer: A systematic review from the International Association for the Study of Lung Cancer (IASLC) Advanced Radiation Technology (ART) Subcommittee","volume":"20","author":"Said","year":"2025","journal-title":"J. Thorac. Oncol."},{"key":"ref_3","unstructured":"Landsteiner, A., Sowerby, C., Ullman, K., Anthony, M., Kalinowski, C., Ester, E., Dahm, P., Lemu, K., Duan-Porter, W., and Wilt, T.J. (2026, September 08). Hypofractionation Radiation Therapy for Definitive Treatment of Selected Cancers: A Systematic Review, Available online: https:\/\/www.ncbi.nlm.nih.gov\/books\/NBK595068\/."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00066-020-01723-8","article-title":"Ultrahypofractionation of localized prostate cancer: Statement from the DEGRO working group prostate cancer","volume":"197","author":"Aebersold","year":"2021","journal-title":"Strahlenther. Onkol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ijrobp.2015.05.004","article-title":"Precision Hypofractionated Radiation Therapy in Poor Performing Patients With Non-Small Cell Lung Cancer: Phase 1 Dose Escalation Trial","volume":"93","author":"Westover","year":"2015","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1158\/1078-0432.CCR-20-2551","article-title":"Phase I and Pharmacologic Study of Olaparib in Combination with High-dose Radiotherapy with and without Concurrent Cisplatin for Non\u2013Small Cell Lung Cancer","volume":"27","author":"Peulen","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"4343","DOI":"10.1200\/JCO.2013.51.5353","article-title":"Dose-Limiting Toxicity After Hypofractionated Dose-Escalated Radiotherapy in Non\u2013Small-Cell Lung Cancer","volume":"31","author":"Cannon","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"ref_8","first-page":"5693","article-title":"Hypofractionated Image-guided Radiation Therapy (3Gy\/fraction) in Patients Affected by Inoperable Advanced- stage Non-small Cell Lung Cancer After Long-term Follow-up","volume":"35","author":"Agolli","year":"2015","journal-title":"Anticancer Res."},{"key":"ref_9","first-page":"842","article-title":"A randomized study comparing two hypofractioned 3-D conformal radiotherapy for stage IIIb-IV non small cell lung cancer","volume":"25","author":"Zygogianni","year":"2020","journal-title":"J. BUON"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1001\/jamaoncol.2021.3186","article-title":"Accelerated Hypofractionated Image-Guided vs Conventional Radiotherapy for Patients With Stage II\/III Non\u2013Small Cell Lung Cancer and Poor Performance Status: A Randomized Clinical Trial","volume":"7","author":"Iyengar","year":"2021","journal-title":"JAMA Oncol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1002\/cncr.29195","article-title":"A prospective nonrandomized phase I\/II study of carbon ion radiotherapy in a favorable subset of locally advanced non\u2013small cell lung cancer (NSCLC)","volume":"121","author":"Takahashi","year":"2015","journal-title":"Cancer"},{"key":"ref_12","first-page":"885","article-title":"A Phase I Study of Hypofractionated Carbon-ion Radiotherapy for Stage III Non-small Cell Lung Cancer","volume":"38","author":"Saitoh","year":"2018","journal-title":"Anticancer Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.ijrobp.2022.03.005","article-title":"Chemoradiation with Hypofractionated Proton Therapy in Stage II\u2013III Non-Small Cell Lung Cancer: A Proton Collaborative Group Phase 2 Trial","volume":"113","author":"Hoppe","year":"2022","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.ijrobp.2022.01.012","article-title":"Phase I Study of Accelerated Hypofractionated Proton Therapy and Chemotherapy for Locally Advanced Non-Small Cell Lung Cancer","volume":"113","author":"Contreras","year":"2022","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ijrobp.2013.03.035","article-title":"Phase 1 Study of Dose Escalation in Hypofractionated Proton Beam Therapy for Non-Small Cell Lung Cancer","volume":"86","author":"Gomez","year":"2013","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.ijrobp.2021.07.1695","article-title":"The Influence of Severe Radiation-Induced Lymphopenia on Overall Survival in Solid Tumors: A Systematic Review and Meta-Analysis","volume":"111","author":"Damen","year":"2021","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1200\/JCO.23.00627","article-title":"Selective Personalized RadioImmunotherapy for Locally Advanced Non\u2013Small-Cell Lung Cancer Trial (SPRINT)","volume":"42","author":"Ohri","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1186\/s13014-019-1317-x","article-title":"Accelerated hypofractionated radiotherapy plus chemotherapy for inoperable locally advanced non-small-cell lung cancer: Final results of a prospective phase-II trial with a long-term follow-up","volume":"14","author":"Parisi","year":"2019","journal-title":"Radiat. Oncol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"381","DOI":"10.4103\/0973-1482.157332","article-title":"Prospective study of special stage II (T2b-3 N0 M0) non-small-cell lung cancer treated with hypofractionated-simultaneous integrated boost-intensity modulated radiation therapy","volume":"11","author":"Zhang","year":"2015","journal-title":"J. Cancer Res. Ther."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1097\/COC.0000000000000140","article-title":"Dose-escalated Hypofractionated Intensity-modulated Radiation Therapy with Concurrent Chemotherapy for Inoperable or Unresectable Non-Small Cell Lung Cancer","volume":"40","author":"Kim","year":"2017","journal-title":"Am. J. Clin. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ijrobp.2018.01.046","article-title":"Phase 1 Study of Accelerated Hypofractionated Radiation Therapy with Concurrent Chemotherapy for Stage III Non-Small Cell Lung Cancer: CALGB 31102 (Alliance)","volume":"101","author":"Urbanic","year":"2018","journal-title":"Int. J. Radiat. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1001\/jamaoncol.2023.6033","article-title":"Accelerated Hypofractionated Chemoradiation Followed by Stereotactic Ablative Radiotherapy Boost for Locally Advanced, Unresectable Non\u2013Small Cell Lung Cancer: A Nonrandomized Controlled Trial","volume":"10","author":"Wu","year":"2024","journal-title":"JAMA Oncol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.prro.2021.06.004","article-title":"Hypofractionated Intensity Modulated Radiation Therapy With Concurrent Chemotherapy in Locally Advanced Non-Small Cell Lung Cancer: A Phase II Prospective Clinical Trial (GASTO1011)","volume":"11","author":"Qiu","year":"2021","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.radonc.2019.10.008","article-title":"Local and regional treatment response by 18FDG-PET-CT-scans 4 weeks after concurrent hypofractionated chemoradiotherapy in locally advanced NSCLC","volume":"143","author":"Walraven","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"109492","DOI":"10.1016\/j.radonc.2023.109492","article-title":"18F-FDG-PET guided vs whole tumour radiotherapy dose escalation in patients with locally advanced non-small cell lung cancer (PET-Boost): Results from a randomised clinical trial","volume":"181","author":"Cooke","year":"2023","journal-title":"Radiother. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"20150966","DOI":"10.1259\/bjr.20150966","article-title":"Accelerated hypofractionated radiotherapy with concomitant chemotherapy in locally advanced squamous cell carcinoma of lung: Evaluation of response, survival, toxicity and quality of life from a Phase II randomized study","volume":"89","author":"Roy","year":"2016","journal-title":"Br. J. Radiol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.radonc.2020.04.033","article-title":"Accelerated hypofractionated radiotherapy with concurrent full dose chemotherapy for locally advanced non-small cell lung cancer: A phase I\/II study","volume":"148","author":"Glinski","year":"2020","journal-title":"Radiother. Oncol."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.prro.2020.09.001","article-title":"Phase II Study: The Outcome of Hypofractionated Involved-Field Radiation Therapy With Concurrent Chemotherapy for the Treatment of Locally Advanced Non-small Cell Lung Cancer","volume":"11","author":"Katsuta","year":"2021","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1186\/1748-717X-8-198","article-title":"High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy\/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: A feasibility study","volume":"8","author":"Liu","year":"2013","journal-title":"Radiat. Oncol. Lond. Engl."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"747","DOI":"10.5603\/RPOR.a2021.0095","article-title":"Short term clinical outcomes of accelerated hypofractionated radiotherapy in inoperable non-small cell lung cancer patients","volume":"26","author":"Aye","year":"2021","journal-title":"Rep. Pract. Oncol. Radiother."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Ren, X.-C., Wang, Q.-Y., Zhang, R., Chen, X.-J., Wang, N., Liu, Y.-E., Zong, J., Guo, Z.-J., Wang, D.-Y., and Lin, Q. (2016). Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy\/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: Preliminary results of an early terminated phase II trial. BMC Cancer, 16.","DOI":"10.1186\/s12885-016-2314-1"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.radonc.2011.01.022","article-title":"A phase II trial of accelerated hypofractionated three-dimensional conformal radiation therapy in locally advanced non-small cell lung cancer","volume":"98","author":"Zhu","year":"2011","journal-title":"Radiother. Oncol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1186\/1748-717X-8-201","article-title":"Dose escalation of accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy\/fraction) with concurrent vinorelbine and carboplatin chemotherapy in unresectable stage III non-small-cell lung cancer: A phase I trial","volume":"8","author":"Lin","year":"2013","journal-title":"Radiat. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.clon.2017.10.010","article-title":"A Phase II Toxicity End Point Trial (ICORG 99-09) of Accelerated Dose-escalated Hypofractionated Radiation in Non-small Cell Lung Cancer","volume":"30","author":"Cagney","year":"2018","journal-title":"Clin. Oncol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.radonc.2016.02.011","article-title":"Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab","volume":"118","author":"Walraven","year":"2016","journal-title":"Radiother. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"9168424","DOI":"10.1155\/2020\/9168424","article-title":"Outcomes of Hypofractional Tomotherapy in Patients with Stage III Nonsmall Cell Lung Cancer Who Are Not Eligible for Surgery or Concurrent Chemoradiation","volume":"2020","author":"Li","year":"2020","journal-title":"BioMed Res. Int."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S0360-3016(00)00750-1","article-title":"Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning","volume":"48","author":"Giraud","year":"2000","journal-title":"Int. J. Radiat. Oncol. Biol. Phys."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"3610","DOI":"10.1200\/JCO-25-00036","article-title":"Simultaneous Durvalumab and Platinum-Based Chemoradiotherapy in Unresectable Stage III Non-Small Cell Lung Cancer: The Phase III PACIFIC-2 Study","volume":"43","author":"Bradley","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2402614","article-title":"Osimertinib after Chemoradiotherapy in Stage III EGFR -Mutated NSCLC","volume":"391","author":"Lu","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1056\/NEJMoa1709937","article-title":"Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer","volume":"377","author":"Antonia","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.radonc.2018.02.023","article-title":"ESTRO ACROP guidelines for target volume definition in the treatment of locally advanced non-small cell lung cancer","volume":"127","author":"Nestle","year":"2018","journal-title":"Radiother. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1016\/j.prro.2025.11.003","article-title":"Dose-Volume Histogram Compendium of Dose Constraints for Treatment Planning: An ASTRO Consensus Paper","volume":"16","author":"Puckett","year":"2026","journal-title":"Pract. Radiat. Oncol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"104833","DOI":"10.1016\/j.canrad.2026.104833","article-title":"Organs at risk radiation dose constraints: 2025 update","volume":"30","author":"Ailloud","year":"2026","journal-title":"Cancer Radiother."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"8513","DOI":"10.1200\/JCO.2022.40.16_suppl.8513","article-title":"Safety results of NRG-LU004: Phase I trial of accelerated or conventionally fractionated radiotherapy combined with durvalumab in PD-L1\u2013high locally advanced non-small cell lung cancer","volume":"40","author":"Lin","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2997\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T08:17:34Z","timestamp":1789633054000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/18\/18\/2997"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,16]]},"references-count":45,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2026,9]]}},"alternative-id":["cancers18182997"],"URL":"https:\/\/doi.org\/10.3390\/cancers18182997","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,16]]}}}